The Week in Review: Feds: Even Those Sold It Did Not Know Contents of SGF-1000

This past summer, Michael Kegley Jr. and Kristian Rhein both pled guilty to felony drug adulteration and misbranding charges in the alleged international Thoroughbred doping conspiracy case. That means they'll avoid trials prior to their sentencings. But it doesn't mean that the voluminous cache of evidence that prosecutors would have used against them won't ever see the light of day.

In fact, just last week, the feds disclosed intriguing documentation about SGF-1000, the adulterated and misbranded purportedly performance-enhancing drug (PED) that was an elixir of choice for now-barred trainer Jorge Navarro, who admitted to injecting it into his horses when he pled guilty in August to one felony drug count. SGF-1000 allegedly also served as “juice” for fellow ruled-off conditioner Jason Servis, but he's still fighting his felony doping charges, even after being implicated by other defendants and allegedly being caught on intercepted phone calls discussing his wide-ranging use of PEDs.

The new intel about SGF-1000 arrived Nov. 15 in the form of a sentencing report for Kegley submitted by the government in advance of his Jan. 6 appearance in United States District Court (Southern District of New York), when he will learn his potential prison fate.

Both Kegley and Rhein are facing maximum three-year terms of incarceration. Rhein's sentencing is Jan. 5, and his report from the government is due Nov. 24.

Kegley is the former sales director for MediVet Equine, the Kentucky-based company that marketed and sold SGF-1000. Rhein is a now-suspended veterinarian formerly based at Belmont Park who has admitted that he and Servis were “leaders and organizers” of a network of associates who performed criminal actions related to doping. The feds also allegedly have Rhein taped on an intercepted phone call bragging that he sold “assloads” of SGF-1000 to racetrackers.

Soon after the arrests of 27 defendants on Mar. 9, 2020, we learned about Servis's alleged conversations with Rhein from June 2019 in which the trainer expressed fears that his purportedly doped MGISW Maximum Security would trigger a positive for SGF-1000. Rhein assured him Max wouldn't, because “they don't even have a test for it in America.”

And this past September, when prosecutors released a separate trove of wiretapped evidence, it was further disclosed that MediVet later in 2019 allegedly attempted to trick the Racing Medication and Testing Consortium (RMTC) into delisting SGF-1000 as a prohibited substance.

The government's sentencing submission from Nov. 15 fills in some previously unknown blanks about how SGF-1000 was marketed, pitched, and positioned during this time frame to maximize sales and avoid scrutiny.

$200 a bottle…but it worked

By the time SGF-1000 had landed in the crosshairs of federal prosecutors in early 2019, MediVet had already “reaped millions of dollars in revenue,” the court document stated. Part of the reason the company was able to rake in enormous profits had to do with bypassing the costs of the rigorous drug approval and registration process required by the Food and Drug Administration (FDA).

“Unlike legitimate drug manufacturers, MediVet spent no funds on studies to demonstrate to the FDA the safety and efficacy of SGF-1000,” the submission stated.

Working in tandem, Kegley and Rhein “both extolled the performance-enhancing benefits of the drug to racehorse trainers.”

Up until the spring of 2019, marketing material for SGF-1000 was routinely provided to purchasers and was readily available on MediVet's website. According to the government, its sellers emphasized “the potent effects of SGF-1000,” which were supposedly derived from “an innovative formulation consisting of Regenerative Proteins, Cytokines, Peptides, potent Growth Factors and Signaling Molecules derived from Ovine Placental Extract.”

The submission further stated that SGF-1000 was explained to trainers as being similar to a vasodilator that would “increase stamina, performance, and overall health.” The materials even listed the growth factors that were purportedly found in SGF-1000, including fibroblast growth factor and hepatocyte growth factor.

“Of course, many jurisdictions prohibited the use of such growth factors on racehorses, particularly where the growth factors are component parts of drugs that are not approved by the FDA, and administered solely to improve a horse's recovery and race performance,” the submission stated.

“Despite the advertised effects of, and ingredients in SGF-1000, the drug's appeal was rooted in the fact that it was undetectable in a horse's system through standard drug screens used in the racing industry, which Rhein repeatedly touted when discussing the drug,” the document continued.

The feds also alleged that despite what Kegley, Rhein, and other MediVet representatives claimed when they were parroting the company's marketing materials, no one pushing the product really had any accurate idea of what was in it.

“Notably, Kegley and his coconspirators did not know the precise contents of SGF-1000 until at least in or about August 2019–years after MediVet had started marketing and selling the drug,” the submission stated. “But [they] believed that no matter the component parts of the drug, it would enhance a horse's performance.”

So too, apparently did trainers. That's why they shelled out $200 a bottle for SGF-1000.

After Servis phoned Rhein on June 5, 2019, to allegedly tell him that Maximum Security had received a dose of SGF-1000 right before an unannounced drug test, “Rhein grew concerned regarding the potential for regulatory scrutiny of SGF-1000, and shared this concern with others at MediVet,” the sentencing submission stated.

The filing continued: “A few weeks later, on July 9, 2019,  Rhein and others affiliated with MediVet convened a conference call in which they discussed the potential for increased scrutiny of the drug. During that call, a participant mentioned that the federal government had prosecuted a racehorse trainer, Murray Rojas, for doping horses, citing it as an example of a case where drug use on racehorses had been pursued by governmental authorities beyond state racing commissions.

“Following the drumbeat of events indicating heightened suspicion of SGF-1000, Rhein and Kegley strategized regarding the best way to divert people's attention away from SGF-1000.

Rather than cease their sales of that drug, Kegley and Rhein instead discussed how they could tweak the labeling of SGF-1000, so as to make it appear innocuous,” the sentencing submission stated.

“You're right, it might help to re-brand it,” the feds allegedly recorded Kegley saying on a wiretap. “We won't mention the word 'growth factor' in any way shape or form…. We can even put on the box, you know, 'dietary supplement for equine.' That way it's not–no one even has to question if it's FDA-approved or not. It's strictly a supplement.”

RMTC Trickery

By the summer of 2019, the push was on at MediVet to try and convince the RMTC that this “supplement” was so harmless that it should be delisted as a banned substance.

“On August 8, 2019, a MediVet representative received a report from Industrial Laboratories reflecting a negative finding (at that time) for certain growth factors,” the court document stated.

Yet that same test did detect, among other prohibited substances, “low levels of acepromazine, levamisole, detomidine, pyrilamine, lidocaine, MEGX, xylazine, and caffeine.”

MediVet's reaction to this disturbing news?

According to the sentencing submission, it was “to request that the negative and positive findings be split into two separate reports. On Sept. 10, 2019, MediVet, through counsel, conveyed the negative findings to the RMTC, while withholding the positive findings.”

Around the same time, MediVet was feeling heat from regulators in New York who were zeroing in on SGF-1000 as an allegedly abused PED.

“In September 2019, MediVet's sales of SGF-1000 hit a significant hurdle,” the sentencing submission stated. “The New York Gaming Commission issued a notice in which it reiterated its longstanding prohibition against the use of growth factors and growth hormones on racehorses, but also specifically named SGF-1000 as a prohibited drug of the type that contained growth hormone or growth factors.”

Yet still, the court document explained, “Kegley and Rhein continued to market and sell SGF-1000” while MediVet “altered the promotional material for SGF-1000 to divert attention and mislead anyone who was unfamiliar with the prior marketing materials description of SGF-1000.”

So whereas the packaging and label for SGF-1000 in July 2019 described it as consisting of “regenerative placental proteins” and being “made in Australia,” by October the drug's description “had been altered to remove any reference to Australia, and was instead described as a 'homeopathic placental extract.'”

Yet by Oct. 14, 2019, MediVet had already learned “that a subsequent test of SGF-1000 did result in findings reflecting the presence of a specific growth factor,” the document stated.

And by the time Kegley and Rhein were arrested five months later, “the website for SGF-1000 had been scrubbed clean, removing any reference to growth factors, and much of the description regarding SGF-1000” itself.

“In short, even after Kegley and others at MediVet had reason to pause and take stock of the illegality of SGF-1000, they nonetheless continued to sell the drug,” the submission stated.

“With full knowledge that SGF-1000 was banned in New York, that a racehorse trainer had been criminally charged for doping, and that law enforcement was beginning to scrutinize the use of SGF-1000 specifically…Kegley and Rhein worked together and with others to deceptively label that drug, and to continue to sell the drug to those in the racehorse industry seeking a competitive advantage,” the document stated.

“Given the proliferation of websites that offer potent PEDs to those in the racehorse industry, similar to that operated by MediVet, a significant sentence is warranted to send a strong signal to others thinking of engaging in such criminality that there will be consequences for their crimes.

“Many actors in the racehorse industry have grown indifferent to, and dismissive of, the notion of obtaining illegal drugs to dope racehorses for profit, and assume that no serious ramifications will follow if they are ever caught,” the submission summed up.

The post The Week in Review: Feds: Even Those Sold It Did Not Know Contents of SGF-1000 appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Leofric Relocates to Darby Dan

Grade I winner Leofric (Candy Ride {Arg}–Lady Godiva, by Unbridled's Song), who had been standing at Rockridge Stud in New York, will relocate to Darby Dan Farm in Kentucky for the 2022 breeding season. The 8-year-old stallion will stand for $7,500 S&N.

“There's a lot to like about Leofric. He has a stallion's pedigree, and his first foals are outstanding,” said Ryan Norton, stallion director at Darby Dan Farm. “Being a Grade I winner by Candy Ride, it makes a lot of sense to bring him to Kentucky now to give him every opportunity to succeed as a stallion and carry on his sire's legacy. We are excited to share him with breeders.”

Leofric won the 2018 GI Clark H., GII Hagyard Fayette S., and GIII West Virginia Governor's S. He was third in that year's GI Woodward S. On the board in 12 of 14 starts, he won eight times and earned $951,040 for owner Steve Landers Racing and trainer Brad Cox.

Leofric retired to stud in 2020 and was represented by his first foals this year. He will stand at Darby Dan as the property of a syndicate.

The post Leofric Relocates to Darby Dan appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Gran Exit For Alegria in Mile Championship

Japanese champion Gran Alegria (Jpn) (Deep Impact {Jpn}) signed off her career with her second consecutive G1 Mile Championship victory, her sixth top-level score, at Hanshin on Sunday. She is the first horse to win back-to-back Mile Championships since Daiwa Major (Jpn) (Sunday Silence) in 2006/07.

Tabbed the heavy favourite at 70 cents on the dollar, the 5-year-old mare was content to race near the rear of the field as Ho O Amazon (Jpn) (King Kamehameha {Jpn}) sped through fractions of :23.70 and :47.60. Jockey Christophe Lemaire had a ton of horse under him at all points in the race, and steered Gran Alegria out widest of all as the field entered the straight. Asked for her run, she responded under confident handling and steamed home to win easily by three-quarters of a length as much the best. Group 1 winner Schnell Meister (Ger) (Kingman {GB}) closed from midpack to report home second, a half-length to the good of Danon the Kid (Jpn) (Just a Way {Jpn}).

“I am relieved and happy,” said Lemaire, who was winning his 40th Japan Racing Association Group 1 and 1,500th race in the JRA's jurisdiction. The most important mission for me in her last run of her career was to bring out the best performance, her true form and she did just that. We were positioned a little further back but it didn't worry me much and she has this really good finishing speed at the stretch like she showed today.

“She's been a special horse since a 2-year-old, winning all those big races and today she showed us again that she's of a different class. I will miss her.”

A group winner at two and third in the G1 Asahi Hai Futurity S. against males in December of 2018, Gran Alegria made just three starts at three, taking the G1 Japanese 1000 Guineas in the spring and the G2 Hanshin Cup at the end of the year and was named Japanese Champion 3-Year-Old Filly. At four, Gran Alegria won three of her four appearances, starting with a second in the G1 Takamatsunomiya Kinen in March. She ended her year with three straight Group 1 wins-the June 7 Yasuda Kinen, Oct. 4 Sprinters S. and Nov. 22 Mile Championship en route to year-end honours as the Japanese Champion Sprinter/Miler. In 2021, she returned with a fourth in the Apr. 4 G1 Osaka Hai, prior to a victory in the G1 Victoria Mile on May 16. Second defending her Yasuda Kinen title in June, she ran third in the 2000-metre G1 Tenno Sho (Autumn) on Oct. 31.

 

Pedigree Notes
Gran Alegria is, in terms of Group 1 wins, the second most decorated progeny of the late Deep Impact (Jpn) after Gentildonna (Jpn), who has 53 Group 1 winners in total. The Northern Farm-bred is among his 179 worldwide black-type winners and 144 group winners. Tapit's broodmare sire career is going from strength to strength, and he also has the listed stakes winner and Group 3 placed Arusha (Jpn) by Deep Impact. Fifty-three progeny out of his daughters have won a black-type race, 24 of them are group winners and his very best so far has been the Mile Championship heroine from his seven Group 1 scorers.

The first reported foal out of the dual Grade I-winning turf star Tapitsfly, who also won the Breeders' Cup Juvenile Fillies Turf back when it was a listed race, Gran Alegria has a winning 4-year-old full-brother named Blutgang (Jpn) (Deep Impact {Jpn}). Her dam sold for $1,850,000 to Katsumi Yoshida out of the Fasig-Tipton November Sale in 2012. Tapitsfly's full-sister Flying Tipat (Tapit) was stakes placed at Indiana Downs, while the fourth dam, the winning Pink Dove (Argument {Fr}) was a half-sister to the 1990 GI Arlington Million hero Golden Pheasant (Caro {Ire}), who also took the Japan Cup in 1991.

Other half-siblings to Pink Dove are Group/Grade 3 winners Seewillo (Pleasant Colony), and Trial By Error (Caro {Ire}). At stud, Pink Dove foaled two stakes winners-Moonshine Hall (Spinning World), third in the GIII Toronto Cup H. and Malli Star (Baldski), a dual stakes winner and runner-up in the GI Del Mar Invitational Oaks. The latter went on to produce Japanese stakes winner Bella Rheia (Jpn) (Narita Top Road {Jpn}), Classic-placed and third in the G1 Queen Elizabeth II Commemorative Cup.

 

Sunday, Hanshin, Japan
MILE CHAMPIONSHIP-G1, ¥252,920,000, Hanshin, 11-20, 3yo/up, 1600mT, 1:32.60, fm.
1–GRAN ALEGRIA (JPN), 121, m, 5, by Deep Impact (Jpn)
                1st Dam: Tapitsfly (MGISW-US, $1,495,503), by Tapit
                2nd Dam: Flying Marlin, by Marlin
                3rd Dam: Morning Dove, by Fortunate Prospect
O-Sunday Racing; B-Northern Farm (Jpn); T-Kazuo Fujisawa;
J-Christophe Lemaire. ¥133,444,000. Lifetime Record: Ch. 3yo
Filly-Jpn, Ch. Sprinter-Jpn, Ch. Miler-Jpn, 15-9-2-2. Werk Nick
   Rating: A+++. *Triple Plus*. Click for the
   eNicks report & 5-cross pedigree.
2–Schnell Meister (Ger), 123, c, 3, Kingman (GB)–Serienholde
(Ger), by Soldier Hollow (GB). O-Sunday Racing; B-Northern
Farm (Jpn); ¥52,984,000.
3–Danon the Kid (Jpn), 123, c, 3, Just a Way (Jpn)–Epic Love
(Ire), by Dansili (GB). (¥100,000,000 Wlg '18 JRHAJUL).
O-Danox Inc.; B-Northern Farm (Jpn); ¥33,494,000.
Margins: 3/4, HF, NO. Odds: 0.70, 3.60, 15.10.
Also Ran: Indy Champ (Jpn), Ho O Amazon (Jpn), Salios (Jpn), Darlington Hall (GB), Soind Chiara (Jpn), Catedral (Jpn), Cadence Call (Jpn), Rainbow Flag (Jpn), Lotus Land, Grenadier Guards (Jpn), Kurino Gaudi (Jpn), Ripresa (Jpn), Sound Kanaloa (Jpn).
Click for the JRA chart & video or the free Equineline.com catalogue-style pedigree.

 

The post Gran Exit For Alegria in Mile Championship appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Candy Ride’s Senbei Romps in Notebook

Senbei romped to the third stakes win of his young career with a front-running victory in the Notebook S. at Aqueduct Sunday. The heavy favorite zipped out to the early lead and was in control through an opening quarter in :23.03. He shrugged off Bustin Pietre after a half in :46.59 and sailed home an easy winner.

“I was confident because the jockey [Manny Franco] looked so comfortable on him,” said winning trainer Christophe Clement. “When Carmouche [Kendrick, aboard No. 3, Bustin Pietre] came to him at the three-eighths, I was a little anxious, but at soon as he shook him up at the quarter-pole, I thought he looked comfortable and he won going away. He's a nice horse.”

Franco added, “He's a very nice sprinter. I wanted to break good and then he did the rest. My plan was to go to the lead and slow down the pace if I could. That's how he likes to run. As soon as I made the lead, I didn't feel too much pressure. I was able to slow down the first part and I knew after that I was going to be tough.”

Senbei opened his career with a 4 3/4-length victory going 5 1/2 furlongs at Saratoga July 18 and followed up with a 2 3/4-length win in the 6 1/2-furlong Funny Cide S. at the historic upstate oval Aug. 27. He suffered his first loss when second in the seven-furlong Bertram F. Bongard S. at Finger Lakes Sept. 26, but cut back to six furlongs and returned to the winner's circle in the Oct. 18 New York Breeders' Futurity last time out.

As for what is next for Senbei, Clement said, “He'll have a break now. We've been squeezing him a little bit. He's had five starts. He's a good horse and a fast horse. It will be interesting to see if he can come back next year and stretch his speed a little bit.”

Sweet Aloha has a yearling colt by Union Rags who sold for $60,000 at last month's Fasig-Tipton October sale. The mare was bred to Twirling Candy last spring. Click for the Equibase.com chart or VIDEO, sponsored by TVG.

 NOTEBOOK S., $97,000, Aqueduct, 11-21, (S), 2yo, 6f, 1:11.49, ft.
1–SENBEI, 122, c, 2, by Candy Ride (Arg)
                1st Dam: Sweet Aloha, by Western Cat
                2nd Dam: Sweet Leilani, by Tagish
                3rd Dam: Mauna Loa, by Hawaii
($280,000 Ylg '20 KEEJAN). O-Reeves Thoroughbred Racing &
Darlene Bilinski; B-Jerry Bilinski (NY); T-Christophe Clement;
J-Manuel Franco. $55,000. Lifetime Record: 5-4-1-0, $364,857.
*1/2 to Filibustin (Bustin Stones), MSW, $309,140; 1/2 to
Indy's Lady (Take Charge Indy), MSW, $202,378.
2–Bustin Pietre, 120, g, 2, Bustin Stones–Amulay, by It's No
Joke. 1ST BLACK TYPE. O/B-Roddy J. Valente (NY); T-Bruce N.
Levine. $20,000.
3–Daufuskie Island, 120, c, 2, Goldencents–Livermore Valley,
by Mt. Livermore. O/B-Robert Hahn (NY); T-Kelly J. Breen.
$12,000.
Margins: 8 1/4, HF, 4HF. Odds: 0.25, 9.30, 5.40.
Also Ran: Bali's Shade, Cool Laoban. Scratched: Kenner.

The post Candy Ride’s Senbei Romps in Notebook appeared first on TDN | Thoroughbred Daily News | Horse Racing News, Results and Video | Thoroughbred Breeding and Auctions.

Source of original post

Verified by MonsterInsights